MA

Medipalli Ambedkar Sastri

Active Director Director DIN 11807655
DIN 11807655 First appointment Jul 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Medipalli Ambedkar Sastri

Medipalli Ambedkar Sastri is a Director at Bridge Pharma Infinity Private Limited (since 2026).

DIN 11807655
Primary Designation Director
First Appointment 07 Jul 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director07 Jul 20262026Active

Directorship timeline

Open interactive timeline →
Bridge Pharma Infinity Private Limited
Premium access

Shareholding and investment profile for Medipalli Ambedkar Sastri

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Medipalli Ambedkar Sastri

Medipalli Ambedkar Sastri currently holds 1 directorship: Bridge Pharma Infinity Private Limited (Director, since 07 Jul 2026).

Medipalli Ambedkar Sastri was first appointed on 07 Jul 2026 as Director at Bridge Pharma Infinity Private Limited.

The current boards of Medipalli Ambedkar Sastri's companies include Roopa (Bridge Pharma Infinity Private Limited), Bharatesh Kidambi (Bridge Pharma Infinity Private Limited), Nagaratna Shastrimath (Bridge Pharma Infinity Private Limited), Rashmi Rudragouda Patil (Bridge Pharma Infinity Private Limited), Suma Mallikarjun Hulikantimath (Bridge Pharma Infinity Private Limited), Usha Kidambi (Bridge Pharma Infinity Private Limited), among others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available